The White House announced reduced pricing for the popular weight-loss drugs made by Eli Lilly and Novo Nordisk.

President Trump announced a deal with Eli Lilly and Novo Nordisk to lower prices on hugely popular weight-loss drugs for Medicare, Medicaid and American patients who pay with their own money.

The list prices of obesity drugs Wegovy and Zepbound are over $1,000, but that's not necessarily what you pay.

President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce ...

Press Release President Donald J. Trump announced agreements with Eli Lilly and Novo Nordisk to reduce prices of available ...

US President Donald Trump announced deals Thursday with pharmaceutical giants Eli Lilly and Novo Nordisk to lower the prices ...

Access to the drugs has been a consistent problem for patients because of their cost — around $500 a month for higher doses — ...

The deal offers popular weight loss drugs to be sold for as low as $149 on President Donald Trump's direct-to-consumer ...

Trump secures a major deal with Eli Lilly and Novo Nordisk to cut obesity drug costs as Medicare expands coverage for ...

The agreement will make Wegovy and Zepbound available to some Medicare enrollees for $245 per month, and starter doses of pill versions, once approved, for $149 monthly.

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...